Management of gout

Scandinavian Journal of Rheumatology

Volumn 37, Issue 2, 2008, Pages 81-89

  Perez Ruiz, F ^a   Schlesinger, N ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPICILLIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZOFURAN DERIVATIVE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN A; DIURETIC AGENT; FENOFIBRATE; INDOMETACIN; LEFLUNOMIDE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PREDNISOLONE; PREDNISONE; PROBENECID; PROTON PUMP INHIBITOR; SULFINPYRAZONE; TRIAMCINOLONE ACETONIDE; URATE; URICOSURIC AGENT;

ABDOMINAL PAIN; ACUTE DISEASE; ALOPECIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRESS SYNDROME; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GOUT; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; LEUKOCYTE FUNCTION; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER TOXICITY; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NEUTROPHIL CHEMOTAXIS; PEPTIC ULCER; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STOMACH ULCER; SYNOVITIS; SYSTEMIC DISEASE; THROMBOPHLEBITIS; TISSUE NECROSIS; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VOMITING;

ACUTE DISEASE; CHRONIC DISEASE; COLD; GOUT; GOUT SUPPRESSANTS; HUMANS; REST; URIC ACID;

EID: 42149116996     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701867372     Document Type: Review

References (129)

1. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987;24:33-6.
2. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416.
3. Schlesinger N, Baker DG, Schumacher HR, Jr. Gout: how well have diagnostic tests and therapies been evaluated? Cur Opin Orthop 2000;11:71-6.
4. Schlesinger N, Baker DG, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001;13:240-4.
5. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
6. Agudelo CA, Schumacher HR Jr, Phelps P. Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis Rheum 1972;15:609-16.
7. Schumacher HR Jr. Crystal induced arthritis: an overview. Am J Med 1996;100(Suppl 2A):46-52.
8. Schlesinger N, Baker DG, Beutler AM, Hoffman BI, Schumacher HR Jr. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4.
9. Dorwart BB, Hansell JR, Schumacher HR Jr. Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum 1974;17:563-71.
10. Weede RP. Poison in the pot: the legacy of lead. Carbondale and Edwardsville: Southern Illinois University Press, 1984:83.
11. Katzung BG, editor, Basic and clinical pharmacology. Norwalk: Appleton and Lange, 1995:536-9.
12. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991;11:196-211.
13. Schlesinger N, Schumacher HR Jr, Catton M, Maxwell L. Colchicine therapy for acute gout. Cochrane Database Syst Rev 2006;(4):CD006190.
14. Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Austr N Z J Med 1987;17:301-4.
15. Paulus HE, Schlosstein LH, Godfrey RC, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1987;17:609-14.
16. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA, RPS, 2002:500 (No. 44).
17. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. Br Med J 2003;327:1275-6.
18. Evans IT, Wheeler MT, Small RE, Breitbach SA, Sanders KM, Roberts WN. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996;23:143-8.
19. Schlesinger N. Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opin Drug Saf 2007;6:625-9.
20. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489-504.
21. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992;327:749-54.
22. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115:165-72.
23. Kelly W, Wortmann RL. In: Kelly WN, editor. Textbook of rheumatology, 4th edn. Philadelphia: Saunders, 1993:1340-51.
24. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
25. Smythe CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973;32:351-3.
26. Rousti A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative double-blind trial. Scand J Rheumatol Suppl 1978;21:15-17.
27. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double-blind comparative study. J Rheumatol 1988;15:1422-6.
28. Weiner GI, White SR, Weitzner RI, Rubenstein HM. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6.
29. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995;26:682-6.
30. Macagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
31. Schumacher HR, Boice J, Dahikh DI, Mulkopadhyay S, Malmstrom K, Ng J, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488-92.
32. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606.
33. Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) 2007;46:1126-32.
34. Gordon GV, Schumacher HR. Management of gout. Am Fam Physician 1969;10:62-6.
35. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979;10:231-54.
36. Fernandez C, Noguera R, Gonzalez JA, Pasquel E. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999;26:2285-6.
37. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990;19:329-36.
38. Alloway JA, Moriarty MJ, Hoogland YT, Nashel D. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20:111-13.
39. Gutman AB, Yu TF. Effects of ACTH in gout. Am J Med 1950;9:24-6.
40. Wolfson WQ, Cohn C, Levine R. Rapid treatment of acute gouty arthritis by concurrent administration of pituitary adrenocorticotropic hormone (ACTH) and colchicine. J Lab Clin Med 1949;34:1766-8.
41. Hollander JL, Brown EM, Elkinton JR. In: Mote J, editor. Proceedings of the second clinical ACTH conference, vol. 2. Philadelphia: Blakston, 1951:122-5.
42. Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002;46:2765-75.
43. Getting SJ, Lam CW, Chen AS, Grieco P, Perretti M. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J 2006;20:2234-41.
44. Getting SJ. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006;111:1-15.
45. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696-9.
46. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
47. Seigel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994;21:1325-7.
48. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2006;35:365-8.
49. Schlesinger N, Moore DF, Sun JD, Schumacher HR. A survey of current evaluation and treatment of gout. J Rheumatol 2006;33:2050-2.
50. Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007;34:1566-8.
51. Rozenberg S, Lang T, Laatar A, Koeger AC, Orcel P, Bourgerois P. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed 1996;63:255-61.
52. Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J. A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988;15:1841-71.
53. Bellamy N, Brooks PM, Gilbert RJ, Campbell J, McCredie MA. Survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989;151:537-51.
54. Stuart RA, Gow PJ, Bellamy N, Campbell J, Grigor R. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis. N Z Med J 1991;104:115-17.
55. Dalbeth N, Haskard DO. Mechanisms of inflammation in gout. Rheumatology 2005;44:1090-6.
56. Zhang W, Doherty M, Bardin T, Barskova V, Conagham P, Gerster J, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
57. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
58. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8.
59. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961;55:179-92.
60. Paulus HE, Schlosstein SH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout: a placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
61. Borstad CG, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gout arthritis. J Rheumatol 2004;31:2429-32.
62. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9.
63. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawsky MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987;3126:1562-8.
64. Perez-Ruiz F, Gonzalez Mielgo FJ, Herrero-Beites A. Optimisation of the treatment of acute gout. Biodrugs 2000;13:45-53.
65. Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000;27:1334-7.
66. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
67. Simkin PA. Management of gout. Ann Intern Med 1979;90:812-16.
68. Schumacher HR Jr. Crystal-induced arthritis: an overview. Am J Med 1996;100:46-52.
69. Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-5.
70. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites AM, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
71. McCarthy G, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991;34:1489-94.
72. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5.
73. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-9.
74. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8.
75. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
76. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-93.
77. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, Garcia-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000;86:287-91.
78. Choi HK. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol 2005;17:141-6.
79. Choi HK, Curham C. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004;51:1023-9.
80. Choi HK, Curhan G. Alcohol and gout. Am J Med 2007;120:e5.
81. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5.
82. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-9.
83. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81.
84. Wurzner GC, Gersterb JC, Chiolero A, Maillard M, Fallab-Stubi CL, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1860.
85. Perez-Ruiz F, Naredo E. Imaging modalities and monitoring measures of gout. Curr Opin Rheumatol 2007;19:128-33.
86. Bosi-Ferraz M, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-14.
87. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic therapy. Adv Exp Med Biol 1998;431:13-18.
88. Perez-Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels. Another insight to allopurinol-related toxicity. J Clin Rheumatol 2005;11:129-33.
89. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002;13:2140-4.
90. Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, et al. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother 2006;40:386-91.
91. Yu TF, Gutman AB. Effect of allopurinol on serum and urinary uric acid in primary and secondary gout. Am J Med 1964;37:885-98.
92. Emmerson BT, Gordon RB, Cross M, Thompson DB. Plasma oxypurinol concentrations during allopurinol therapy. Br J Rheumatol 1987;26:445-9.
93. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, et al. Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988;23:423-8.
94. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
95. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbility and mortality. Arthritis Rheum 1986;29:82-7.
96. Vazquez-Mellado J, Meoño Morales E, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
97. Day RO, Graham GG, Hicks M, McLachlan A, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007;46:623-44.
98. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15.
99. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
100. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
101. Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D'Angelo WA. Allopurinol hepatotoxicity. A case report and review of the literature. Arthritis Rheum 1977;20:1546-9.
102. Boston Collaborative Drug Surveillance Program. Excess of ampicillin rashes associated with allopurinol or hyperuricemia. N Engl J Med 2007;286:505-7.
103. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bowes Banvick JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2007.
104. Rodevant E, Sletvold O, Kvande KT. Side effects of allopurinol. Tidsskr Nor Laegeforen 2004;124:2618-19.
105. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Edou H, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2007;15:164-73.
106. Thompson GR, Duff IF, Robinson WD, Galindez H. Long term uricosuric therapy in gout. Arthritis Rheum 1962;5:384-96.
107. Gutman AB. Uricosuric drugs, with special reference to probenecid and sulfinpyazone. Adv Pharmacol 1966;4:91-142.
108. Schepers GW. Benzbromarone therapy in hyperuricemia, comparison with allopurinol and probenecid. J Int Med Res 1981;9:511-15.
109. Goldfrab E, Smythe CJ. Effects of allopurinol, a xanthine-oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum 2007;9:414-23.
110. Reinders MK, Van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007;26:1459-65.
111. Yamamoto T, Moriwaki Y, Takahashi S, Suda M, Higashino K. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991;50:631-3.
112. Jain, Ryan JR, McMahon FG, Noveck RJ. Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum 1974;17:149-57.
113. Sinclair DS, Fox IH. The pharmacology of the hypouricemic effect of benzbromarone. J Rheumatol 1975;2:437-45.
114. Yu TF. Pharmacokinetic and clinical studies of a new uricosuric agent -benzbromarone. J Rheumatol 1976;3:305-12.
115. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002;85:S40-7.
116. Ferber B, Bader U, Matzkues F. The action of benzbromarone in relation to age, sex and accompanying diseases. Adv Exp Med Biol 1980;122A:287-94.
117. Maly J, Schuck O. The influence of benzbromarone and its combination with hydrochlorothiazide on renal excretion of uric acid and electrolytes. Int J Clin Pharmacol Ther Toxicol 2007;28:443-5.
118. Zurcher RM, Bock HA, Thiel G. Excellent uricosuric effect of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994;9:548-51.
119. Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone. Arthritis Rheum 1976;19:183-90.
120. Perez-Ruiz F, Calabozo Raluy M, Herrero Beites A, Duruelo J, Ruibal A, Garcia Erauskin G. Utility of urine spot samples for the follow-up of uricosuric therapy. Rev Esp Reumatol 2007;28:57-61.
121. Walter-Sacks I, de Vries JX, von Bufnoff A, Pfleilschifster V, Raedsch R. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis: evidence for active benzbromarone metabolites? Eur J Med Res 1995;1:16-20.
122. McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 2007;20:1833-42.
123. Jansen TL, Reinders MK, Van Roon EN, Brouwers JR. Benzbromarone withdrawn form the European market: another case of 'absence of evidence is evidence of absence'? Clin Exp Rheumatol 2004;22:651-2.
124. Perez-Ruiz F. New treatment for gout. Joint Bone Spine 2007;74:313-15.
125. Perez-Ruiz F, Nolla JM. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol 2003;9:215-18.
126. Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974;33:304-7.
127. van Lieshout-Ziudema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993;20:1383-5.
128. Gast LF. Withdrawal of long-term antihyperuricemic therapy in patients with tophaceous gout. Clin Rheumatol 1987;6:70-3.
129. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006;55:786-90.